F2G Ltd announces the appointment of John H. Rex as Chief Medical Officer

Written by UMIP on . Posted in News

MANCHESTER, UK – 05 December 2016 – F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of John H. Rex, MD, FACP to the position of Chief Medical Officer, effective from 2nd November 2016.

Dr Rex is a distinguished research scientist and a key opinion leader in the field of infectious disease therapy, in particular antifungal agents. He held the position of Senior Vice President and Head of Infection, Global Medicines Development at AstraZeneca until October 2016. Prior to joining AstraZeneca in 2003, Dr Rex was Professor of Medicine at the University of Texas Medical School at Houston. Dr Rex has been the Industry Representative on the US FDA Anti-Infective Drug Advisory Committee (2007-2011), has served as Chair of the Consensus Committee on Microbiology for the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS), is a member of the Wellcome Trust Seeding Drug Discovery Committee, was formerly an Editor for Antimicrobial Agents and Chemotherapy and currently serves on several editorial boards. He holds a BA in Biochemistry from Rice University as well as an MD from Baylor College of Medicine in Texas. Dr Rex has served as a non-executive director of F2G since September 2012 and is an Operating Partner at Advent Life Sciences.

Ian Nicholson, Chief Executive Officer, F2G Ltd commented: “John’s guidance and insight have been instrumental in shaping F2G’s development and regulatory strategy. We are delighted that he is now able to increase his commitment to the company as we progress our new class of antifungal agents into our next clinical trials.”

John Rex added: “I am delighted to have the opportunity to work more closely with F2G as we take the first orotomide antifungal forward through Phase 2 and Phase 3. Just as with antibacterial resistance, antifungal resistance is a growing threat and F2G’s discovery of an entirely novel class of IV/PO antifungal agent is a key part of the global response to this challenge.”

About F2G Ltd: F2G is a world-leading UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections, with experienced management & board. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides are active against Aspergillus and other rare and resistant moulds and act via a completely different mechanism than currently marketed antifungal agents. Due to their new mechanism of action, orotomides are active against fungal infections resistant to current therapies, a growing problem globally. A limited Phase II study for F901318 is planned imminently with pivotal registration trials in Invasive Aspergillosis planned for 2017 based on an accelerated regulatory pathway agreed with the relevant agencies. F901318 is being developed both as IV and oral formulations and promises to have a safe and well-tolerated profile. The company recently announced a $60 million financing to develop its pipeline of novel therapies to treat life threatening invasive fungal infections.

www.f2g.com

New Project Engineer Joins Graphene Enabled

Written by UMIP on . Posted in News

Ushpal Thind

Ushpal Thind

Ushpal Thind, an experienced mechanical engineer, has joined Graphene Enabled Systems Ltd, The University of Manchester’s graphene and 2D materials commercialisation business.

Previously a test engineer for the micro-CHP and utilities business, Flow Products, based in Capenhurst Cheshire, Ushpal brings a wealth of experience in industrial product design and manufacturing know-how.

Ushpal will work closely with the academic teams at the University, industrial partners, suppliers and customers.  As well as being an experienced design engineer, Ushpal has an MSc in Materials Science and Engineering from Delft University of Technology in the Netherlands and a BEng in Mechanical Engineering from Imperial College London.

 

 

 

Graphene Enabled Systems Ltd, which is headquartered on Grafton Street in Manchester, is owned by the University. The new company’s mission is to create a number of highly profitable ‘spin-off’ businesses based on the University’s graphene patents. The University expects that many of these future ‘spin-off’ businesses will be based in and around Manchester, creating new jobs in the region and benefiting the local economy.

Using the University’s patents and working closely with scientists, Graphene Enabled will seek out new markets for graphene-based products. Once these markets have been identified, Graphene Enabled will create high-quality product prototypes which will showcase the technology to potential industrial partners and customers.

As an important part of the University’s graphene strategy, Graphene Enabled works in close collaboration with the University’s research teams, innovation and IP groups (UMI3 and UMIP), the National Graphene Institute (NGI) and, in 2018 and beyond, the new Graphene Engineering Innovation Centre (GEIC).

Andrew Wilkinson, Graphene Enabled’s CEO, commented: “We are very excited that Ushpal has joined us. His experience in product design and industrialisation will help to create high quality product demonstrators and prototypes capable of exciting customers in a wide range of markets and applications. In the coming months we will continue to build our engineering team, enabling us to accelerate the pace at which we bring new product concepts to market.”

For further information about Graphene Enabled, please visit our website www.graphene-enabled.com and follow us on Twitter @GrapheneEnabled.

 

Success for Manchester at the 2016 Northwest Bionow Awards

Written by UMIP on . Posted in News

(From left to right: Dr Bianca Price, Professor Curtis Dobson and Dr Nishal Govindji-Bhatt)

(From left to right: Dr Bianca Price, Professor Curtis Dobson and Dr Nishal Govindji-Bhatt)

Around 400 people from the Northwest’s biomedical sector gathered on 24th November at the 15th Northwest Biomedical Awards at Mere Golf and Country Club, Cheshire. This prestigious awards dinner celebrates key achievements from companies and individuals who have made a significant contribution to the biomedical sector during 2016. The evening was hosted by comedian and broadcaster Paul Sinha, one of the stars of the ITV quiz The Chase.

University of Manchester spin-out, MicroBiosensor Ltd, won the Bionow Healthcare Project of the Year Award for their InfectDetect project. The company, which spun-out of the Medical Device Biology Group in the Division of Pharmacy and Optometry, has devised and manufactured a prototype simple novel antimicrobial susceptibility diagnostic to prevent hospital admission due to urinary tract infection. The new project, led by Dr Nishal-Govindji-Bhatt and Dr Duncan Henderson, should provide appreciable savings to the NHS, impact the rise of antimicrobial resistance, as well as reduce suffering in vulnerable clinical populations. The award was sponsored by TRUSTECH.

Professor Curtis Dobson, Chairman and Founder of MicroBiosensor, comments: ”It was fantastic news for Microbiosensor to win this Award, which recognises the dramatic progress we have made this year in developing a second product featuring our exciting proprietary technology. Microbiosensor now has two high quality products nearing a CE Mark, and these are poised to have a major global impact, both delivering significant savings for the healthcare providers and improving patient outcomes.”

University of Manchester Research Fellow Dr Bianca Price (who is also based in the Medical Device Biology Group) won the Bionow Promising Technologist of the Year Award for her work in creating an innovative ‘infected wound in a dish’. The model has evaluated anti-infective products from different industrial collaborators, including a novel wound filler and antimicrobial dressings. The award was sponsored by Seqirus.

Dr Price comments: “It is wonderful to be acknowledged for innovative work that has real world impact in this way. The model developed in the Medical Device Biology Group has generated lots of interest in the wound care sector as a relevant way to test movement and efficacy of antimicrobials released from medical devices. We will continue to develop and apply this model as well as other complimentary approaches over the coming years.”

Congratulations also go to colleagues at the Greater Manchester Academic Health Science Network for winning the Bionow Business Services Award, sponsored by Skills and Growth Company.

To cap the night off, University spin-out, F2G Ltd, won the Bionow Investment Deal of the Year Award for their $60M financing round. F2G is an established Manchester-based specialist antifungal company developing a completely new class of antifungal agents to treat life threatening invasive fungal infections. The award was sponsored by QIAGEN Manchester.

The complete list of winners is as follows:

The 2016 winners are:

  • Bionow Start Up of the Year Award – Aptus Clinical – Sponsored by RSM
  • Bionow Healthcare Project of the Year Award – MicroBiosensor – Sponsored by TRUSTECH
  • Bionow Project of the Year Award – Cobra Biologics- Sponsored by Waters Corporation
  • Bionow Product of the Year Award – Magnesium Elektron – Sponsored by Innovation Agency
  • Bionow Technical Service Award – Perfectus Biomed – Sponsored by Appleyard Lees
  • Bionow Business Services Award – Greater Manchester Academic Health Science Network – Sponsored by Skills and Growth Company
  • Bionow Promising Technologist of the Year Award – Dr Bianca Price – Sponsored by Seqirus
  • Bionow Investment Deal of the Year Award – F2G Ltd – Sponsored by QIAGEN Manchester
  • Bionow Outstanding Contribution Award – Alan Boyd- -Sponsored by Sci-Tech Daresbury
  • Bionow Company of the Year Award – Shield Therapeutics – Sponsored by AstraZeneca

For more information about Bionow, please visit www.bionow.co.uk

The Bionow Awards Dinner was sponsored by Manchester Science Partnerships, Appleyard Lees, CY Partners, Redx Pharma and World Courier.

Intellectual Property Development & Partnering Manager

Written by admin on . Posted in Vacancies

  • Technology Transfer
  • Manchester
  • Permanent position
  • Top 3 UK research university
  • Life sciences focus
  • Development of spin-out companies and licence opportunities
  • Join a strong, well-resourced team
  • £50,906 plus bonus scheme and benefits package

The University of Manchester Intellectual Property (UMIP) is the University’s agent for Intellectual Property (IP) management and commercialisation. UMIP is a division of UMI3 Ltd, the wholly owned innovation company of The University of Manchester. UMIP’s role is to commercialise intellectual property (IP), knowhow and technology developed at the University. Since its inception in 2004, UMIP has created 40 spin-out companies, managed over £300m of third party investment into the University’s spin-outs and brokered over 4,800 licences and assignments. UMIP is widely recognised as being amongst the leading university technology transfer organisations in the UK.

The successful candidate will join a team of experienced technology transfer professionals managing a portfolio of IP commercialisation projects across the entire breadth of research output at the University of Manchester. Your key objective is to manage a portfolio of innovations proactively, predominantly focussed in the life sciences area, with the goal of creating new spin out companies and licensing IP to industry. You will complete market analysis, establish a network of contacts and forge partnerships with industry for technology development. Planning projects, securing funding for market focused development, managing IP and successfully executing against plans are key aspects of this role. Success of the team in accessing translational funding, collaborative industrial funding or early-stage venture funding through our relationship with IP Group is a key deliverable, as is driving the portfolio to transaction/investment phase.

Candidates will have a life sciences background, and will preferably be educated to PhD level or equivalent. Applicants will have previous experience of management of collaborative projects, ideally in a technology transfer or industrial innovation environment. You will have strong project management and influencing skills, and be passionate about translating early stage technology into new products and services. You will be commercially focused, with a highly proactive approach to problem solving and the development of the networks essential for effective delivery of goals. This role offers exciting challenges and opportunities for the successful candidate to become a key player within the UMIP team.

Please apply with your CV and current salary details to Mary Williams (mary.williams@umip.com) at UMIP, Incubator Building, 48 Grafton St, Manchester M13 9XX. For further information, call Leanne Burgin, Team Leader, IP Development & Partnering on 0161 306 8514.

Closing Date: Friday 23rd December 2016

Click here for job description

Head of Commercial Transactions

Written by admin on . Posted in Vacancies

  • Licensing intellectual property
  • Creating spin-out businesses
  • Manchester
  • £70K plus bonus scheme and benefits package
  • UMIP is an Investor in People and an equal opportunities employer

The University of Manchester Intellectual Property (UMIP) is the University’s agent for Intellectual Property (IP) management and commercialisation. UMIP is a division of UMI3 Ltd, the wholly owned innovation company of The University of Manchester. UMIP’s role is to commercialise intellectual property (IP), know how and technology developed at the University. Since its inception in 2004, UMIP has created 40 spin-out companies, managed over £300m of third party investment into the University’s spin-outs and brokered over 4,800 licences and assignments. UMIP is widely recognised as being amongst the leading university technology transfer organisations in the UK.

Due to a reorganisation of our structure, a new senior role has been created within UMIP, that of Head of Commercial Transactions. This individual will be responsible for the negotiation of favourable commercial terms for all major licensing, assignment, and spin out transactions working in concert with our IP Development and Partnering Managers. (S)he will lead the Commercial Transaction Project Team which co-ordinates all relevant internal stakeholders driving deal-making activity, and be a key member of the Divisions Management Team. The role provides a creative and experienced individual with the scope to utilise novel business approaches to enable UMIP to commercialise its IP in an efficient and effective manner, securing impact and enhancing the reputation of the University.

The Head of Commercial Transactions will have one direct report and will work with them will develop and maintain excellent working relationships with our spin outs, investors, corporate partners and licensees.

Candidates for this exciting role will be thoroughly commercial and intellectually strong, with broad based skills gained in progressive and respected organisations. You will be educated to at least degree level in a scientific or business subject and in addition will preferably hold a PhD and/or MBA. You will have at least 10 years’ experience in technology transfer, enterprise development, business start-ups, business innovation or licensing in an academic, corporate or professional environment at a senior level. You will be an excellent negotiator with a comprehensive deal sheet, and will be an articulate and able presenter and networker.

For such an individual, we offer a generous salary, bonus scheme and benefits package and the opportunity to join a dynamic, forward-thinking technology transfer company associated with one of the UK’s top research universities.

Written applications, enclosing CV, to Mary Williams.
Email to mary.williams@umip.com
or by post FAO Mary Williams, UMIP, The Incubator Building, 48 Grafton St, Manchester M13 9XX.

Candidates selected for interview will be notified by email. Unsuccessful applicants will not be notified; should you not have received a response two weeks after the closing date for applications, we regret that your application will not have been successful.

UMI3 is an Investor in People and an equal opportunities employer.

Closing Date: 25th November 2016.

Click here for job description

UMIP - REPUTATION AND VALUE THROUGH INTELLECTUAL PROPERTY®

Privacy Policy / Terms and Conditions / © Copyright 2015 The University of Manchester Intellectual Property / Created by HTP Digital Marketing Agency

The University of Manchester Intellectual Property ("UMIP") acts solely as agent for the University in relation to any matter relating to intellectual property ("IP") and know how created at the University. This is whether such IP is created by employees, students or others. UMIP does not represent anyone else in such matters. If anyone else requires advice in relation to such IP then they must take their own independent legal advice.